Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — Investor Presentation (February 2021)
27 slides from Clearpoint Neuro's investor presentation, Feb 19, 2021
Slide 1: ClearPoint Neuro Investor Presentation February 2021
Rag ower” : : ec. ae e0e " s ~ Sa . -" A Pe 7 CLEARPOINT NEURO WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY.. ; hs . y Joe Burnett, President and CEO [; February 2021 Nasdaq: CLPT ||
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Statements herein concerning ClearPoint Neuro, Inc. (the “Company”) plans, growth and strategies may include forward- looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance
Slide 3: Two Opportunities, One Platform
Our Company ClearPoint Neuro: Two Opportunities, One Platform CLEARPOINT Leveraging a Common Navigation Engine, Installed Base and Clinical Support Channel A Biologics & Drug Delivery Company with a Broad A Medical Device Company with an Innovative Portfolio of Pharma Partners and Indications with a
Slide 4: ClearPoint Neuro: A Proven Platform
Our Company ClearPoint Neuro: A Proven Platform Key Products: FDA C€ Marked Platforms HEADQUARTERS TRAINING & INNOVATION CENTER Irvine, CA Solana Beach, CA 2020 REVENUE CASH $12.8m” $20.1m” 5 15% Razor / Razorblade model with 85+ % of U.S. PATENTS ISSUED GROSS MARGIN 65 71%" J revenue from single- C
Slide 5: Limitations of Traditional Stereotactic Neurosurgery
Limitations of Traditional Stereotactic Neurosurgery Lack of Real-Time Image Guidance PRIMARY CHALLENGE For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head MRI is the best imaging tool for the brain Large, metallic frames are not MRI compatible Big Iron
Slide 6: Our Platform — Procedure Overview
Our Platform — Procedure Overview The ClearPoint® Neuro Navigation System esse CLEARPOINT © 2021 CLEARPOINT NEURO | °38° NEURO
Slide 7: SmartFrame XG and SmartFrame Array
SmartFrame® XG SmartFrame® Array \ \. cay At prepa SmartFrame Array Tower with “virtual array” Software and next generation robotic system with increased automation and enabling software (In Development, Not Commercially Available) SmartFrame XG Trajectory Tower _ with ClearPoint 2.0 Software 2. CLE
Slide 8: The ClearPoint Maestro Brain Model
Our Platform The ClearPoint ‘Maestro’ Brain Model Licensed and Jointly Developed with Philips 1. Shape Constrained, triangular mesh model enables point-based correspondence across multiple subjects 2. Fast and capable of peri-procedural imaging without CPU acceleration 3. This model is the basis for
Slide 9: Our MRI-guided therapy platform is currently being used
Our MRI-guided therapy platform is currently being used to... SIEMENS IMRIS G ee CLEARPOINT PIC) ©eyager THERAPEUTICS GENE THERAPIES (@ Bluekock ENE — charles river ..with 25 total commercial and academic partners Medtronic ) Abbott Boston, Scientific @ NELRO Medtronic MONTERIS MEDICAL © 2021 CLEARP
Slide 10: And Growing
.. and Growi f Charles River Labs (Laval, Canada), > Nationwide Children’s Children’s Mercy Hospital CHOA Scottish Rite ¥ 2 Le Bonheur ge Fairfax Willis- raison Oklahoma State Unive Cincinnati Jewish Children’s National
Slide 11: Biologics & Drug Delivery
Biologics & Drug Delivery
Slide 12: Why ClearPoint?
Why ClearPoint? Benefits of ClearPoint 1. Select and confirm the most accurate trajectory before insertion using live MRI Guidance 2. Identify peri-procedural safety issues live instead of after the patient is closed (i.e., hemorrhage) 3. Confirm proper target coverage with drug before closing the p
Slide 13: Patient Treatment Opportunity/Year
PATIENT TREATMENT OPPORTUNITY/YEAR 1. Biologics & Drug Delivery Estimated $1.5B* Market Opportunity As Platform for Gene Therapy 200,000 100,000 10,000 i Huntington : ALS Disease i ~e120M4 ~$120M 220M Angelman 5,000 Syndrome Friedreich’s ES Multiple System Ataxia Atrophy ~$60M! ~$90M’ 1,000 H iffuse
Slide 14: Specialized Consultation for Pharmaceutical Customers
1. Biologics & Drug Delivery Specialized Consultation for Pharmaceutical Customers Custom Protocol Solutions for Cannula Builds Consultation Pre-Clinical Programs Data Management Network of Neurosurgeons Clinica ois: CLEARPOINT © 2021 CLEARPOINT NEURO a
Slide 15: Navigation Device & Therapy
Navigation Device & Therapy
Slide 16: Deep Brain Stimulation
le Deep The ClearPoint® Neuro Navigation Platform is used to accurately place leads in the appropriate targeted structure. The leads are connected ina separate procedure to a neurostimulator implanted near the collarbone. Deep brain stimulation (DBS) uses a surgically implanted medical device, simil
Slide 17: Neuro Navigation (DBS): Gaining Share in a Growing Market
2. Neuro Navigation (DBS Deep Brain Stimulation Gaining Sha na Growing Market B Sctentific Medtronic cS) ee Parkinson’s Patient Population (US) 1.2M Patients with Parkinson's disease 1M Patients diagnosed and treated (+60K newly diagnosed/year 240K ~24% eligible for DBS 5% actual implants/year NEURO
Slide 18: Improved Navigation & Technology, New Indications Drive DBS Growth
2. Neuro Navigation (DBS) Improved Navigation & Technology, New Indications Drive DBS Market Growth of 10%+ CAGR 2020-2025 New Indications in Trials | Treatment Populations Epilepsy* 2 million+ Obsessive Compulsive Disorder (OCD)? AGemnllitor Alzheimer’s Disease? 6 million+ Severe Depression* 10 mil
Slide 19: New Therapy Devices: Laser Therapy
3. New Therapy Devices ClearPoint Neuro Laser Therapy — Capturing the Entire Procedure LITT uses laser energy to destroy unwanted cells TRANBERG® Laser * Today MRI is required during LITT procedures to precisely monitor and controls the temperature and thermal dose from that laser. INFLEXION™ Head F
Slide 20: New Therapy Devices: Significant Addressable Market
3. New Therapy Devices Significant Ad able Neuro M Medtronic — .°*-.::, MONTERIS LiTT for Epilepsy - Total Addressable Patient Population 150K Patients with Epilepsy 50K Epileptic Patients Resistant to Medication y” Patients with Focal, Mesial Temporal Epilepsy LiTT for Tumors - Total Addressable Pa
Slide 21: New Global Showcase Site
New Global Showcase Site ClearPoint Cove Training and Innovation Center — Solana Beach, CA * Intimate training experience for surgeons and staff to perform mock procedures and provide pipeline feedback * Showcase new technology for Pharmaceutical Drug Delivery partners Home for remote support specia
Slide 22: Global Scale: 4 Pillar Growth Strategy by 2025
GLOBAL SCALE Expand Footprint OUS Open WW Training / Remote Support Facility Launch Robotic Platform 4 Pillar Growth Strategy by 2025 Target Indications of > 150,000 procedures per year represents Potential Addressable Market for CLPT of $1B+ NEW THERAPY DEVICES Launch Maestro Brain Model and Apps E
Slide 23: Financials
miatclateltels see CLEARPOINT: © 2021 CLEARPOINT NEURO 33 | 2
Slide 24: Growth in Case Volume and Revenue
NO oO S) Growth in Case Volume and Revenue $12.8 @ Biologics and Drug Delivery ®™ Capital and Software ™@ Functional Neurosurgery *COVID impact on Elective Procedures 670 682* 2014 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 253 CLEARPOINT © 2021 CLEARPOINT NEURO 2
Slide 25: CLPT Capabilities Executive Summary
CLPT CAPABILITIES Executive Summary Baa o5 alll sia, CLEARPOINT Unique Platform technology enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders Pipeline of new revenue streams from product improvements, biologic and drug delivery partnerships
Slide 26: Nasdaq site
nasdarsite Na Sd aq Nasdaq G am Composi plow Compos' < 1.57% site Nasdaq100 powjonEs comp * 9, +180 Snesn COMP 4 0.209 ssPg00 q me : os, & sthoahy +19.21 0% NASDAQI00 in 0.29% DJI ov 0.09% a oe. cisco rs 427.88 9,623.58 -26.93 29,396.38 SP500 go 338007 COMCAST 2 PEPSICO matchgroup @ amazon’ ry =. eS
Slide 27: ClearPoint Neuro
CLEARPOINT NEURO
ClearPoint Neuro — Investor Presentation (February 2021) on 6ix